Pembrolizumab in Combination with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: Clinical Evidence, Regulatory Approval and Therapeutic Implications
Crossref DOI link: https://doi.org/10.17352/sjggt.000025
Published Online: 2026
Update policy: https://doi.org/10.17352/crossmark-policy
Naseer, Sulaiman
